SPRY4 and lung carcinoma: The antiproliferative capacities of the Kallmann-associated Spry4 mutant exceed those of the corresponding wt, when expressed in DMS114, a lung cancer-derived cell line where FGFR1 amplification was identified as a driver mutation.